Table 2.

Summary of available data on secukinumab use in challenging treatment scenarios

Population	Number of publications	Number of patients	Sex (male/female)	Age	Key safety outcome
Special populations
Pregnant [15, 17, 19]	3	584	Female; 13.5% paternal exposure [15, 17]	31.1 years (mean) [15]; 45 years [19]	No evidence for increased rates of AEs
Pediatric [24, 25]	2	2	2/0	2 patients: 4 years (deficiency of the IL-36 receptor antagonist) [24]; 13 years (recalcitrant chronic erythrodermic PsO) [25]	Improved skin and no AEs
Elderly [28]	1	67	41/26	69.3 years (mean)	Safety profile consistent with general population
Erythrodermic PsO [80–82]	3	16	14/2	36–59 years (range across studies) [80, 81] 42.6 (11) years (mean [SD]) [82]	Secukinumab is effective and safe
Chronic illnesses
LTBI [36, 39, 40]	3	154	9/3 [40]	29–77 years (range) [40]	Only 1 patient reported LTBI
HBV/HCV [39, 50–52]	4	75	53/12 [50–52]	42–66 years (range across studies) [50–52]	No virus reactivation in patients receiving antiviral prophylaxis
HIV [58]	1	1	0/1	48 years	Complete skin clearance and HIV viral load remained undetectable
MS [63, 64]	2	39	18/21	42 years [63]; 36.1 (9.8) years (mean [SD]) [64]	Reduced MRI lesions with secukinumab
Malignancies	No available clinical data on secukinumab use in patients with PsO and comorbid malignancies

Not all studies included demographic information for secukinumab-treated patients in special populations or with chronic illnesses

HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, LTBI latent tuberculosis infection, MRI magnetic resonance imaging, MS multiple sclerosis, PsO psoriasis